Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate‐Lowering Therapy During Remission: A Mixed‐Methods Study
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Iris Rose Peeters und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sint Maartenskliniek, Ubbergen, the Netherlands and Radboud University, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Gout, Gout Suppressants, Uric Acid, Remission Induction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Long‐term gout management is based on reducing serum urate by using urate‐lowering therapy (ULT). A lifelong treat‐to‐target approach is advocated, although a ULT (taper to) stop attempt can be considered (treat‐to‐avoid symptoms approach) during remission. Exploring the beliefs of patients with gout on long‐term ULT strategies during remission is important for optimizing gout management. We aimed to identify factors that influence the decision for continuation or discontinuation of ULT and to determine their relative importance according to patients with gout in remission.
Methods
A mixed‐methods design was used. First, semistructured interviews (substudy 1) were conducted to identify barriers and facilitators for the (dis)continuation of ULT using inductive thematic analysis. Afterwards, these barriers/facilitators were summarized into neutrally phrased items and used in a maximum difference scaling study (substudy 2) to determine their relative importance using the rescaled probability score.
Results
Substudies 1 and 2 included 18 and 156 patients, respectively. Substudy 1 yielded 22 items within 10 overarching themes. Substudy 2 revealed that the perceived risk of joint damage and gout flares and that ULT use gives some assurance were the most important items. The costs, ease of receiving ULT, and its practical use were the least important items.
Conclusion
These results can aid shared decision‐making and provide input for what is important to discuss with patients with gout in remission when they consider ULT discontinuation. The emphasis should be on the risk of having gout flares and joint damage, not so much on facilitating how easily medication is received.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sint Maartenskliniek, Ubbergen, the Netherlands and Radboud University, Nijmegen, the Netherlands.
- Sint Maartenskliniek, Ubbergen, the Netherlands.
- Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Iris Rose Peeters, Frouwke Veenstra, Johanna E Vriezekolk
Zitieren
APA
Peeters, I. R., Veenstra, F., Wanten, S. A. C., Vriezekolk, J. E., van den Ende, C. H., den Broeder, A. A., van Herwaarden, N., Verhoef, L. M., & Flendrie, M. (2024). Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate‐Lowering Therapy During Remission: A Mixed‐Methods Study. Arthritis Care & Research. https://doi.org/10.1002/acr.25392
Vancouver
Peeters IR, Veenstra F, Wanten SAC, Vriezekolk JE, van den Ende CH, den Broeder AA, et al. Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate‐Lowering Therapy During Remission: A Mixed‐Methods Study. Arthritis Care & Research. 2024. doi:10.1002/acr.25392
BibTeX
@article{Peeters2024,
author = {Peeters, Iris Rose and Veenstra, Frouwke and Wanten, Sophie A C and Vriezekolk, Johanna E and van den Ende, Cornelia H and den Broeder, Alfons A and van Herwaarden, Noortje and Verhoef, Lise M and Flendrie, Marcel},
title = {Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate‐Lowering Therapy During Remission: A Mixed‐Methods Study},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25392}
}
EUVIMED